CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease
OBJECTIVE: To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behçet's disease (BD) in a cohort of Italian patients.
METHODS: One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations.
RESULTS: The distribution of the CCR5Δ32 genotype differed between BD patients and controls (P = 0.02). The CCR5Δ32 allele was more common in BD patients than in controls [P = 0.02, odds ratio (OR) 2.28 (95% CI 1.1, 4.8)]. Carriers of the CCR5Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were significantly more common in BD patients than in controls [P = 0.02, OR 2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was 7.1%. In categorizing patients according to gender, the association between CCR5Δ32 polymorphism and BD was similar in females and males (ORs 2.76 and 2.0, respectively). No significant differences were found when the frequencies of clinical manifestations were compared between CC5RΔ32 allele carriers and non-carriers.
CONCLUSION: CCR5Δ32 polymorphism is associated with an increased susceptibility to develop BD. Chemokines may have a role in the pathophysiology of BD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Rheumatology (Oxford, England) - 51(2012), 12 vom: 19. Dez., Seite 2141-5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Atzeni, Fabiola [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
HLA-B Antigens |
|---|
| Anmerkungen: |
Date Completed 01.02.2013 Date Revised 03.12.2012 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1093/rheumatology/kes238 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM220915296 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM220915296 | ||
| 003 | DE-627 | ||
| 005 | 20231224050602.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/rheumatology/kes238 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0736.xml |
| 035 | |a (DE-627)NLM220915296 | ||
| 035 | |a (NLM)22966075 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Atzeni, Fabiola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2013 | ||
| 500 | |a Date Revised 03.12.2012 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To evaluate the potential role of CC chemokine receptor 5 (CCR5)Δ32 polymorphism in the susceptibility to and clinical expression of Behçet's disease (BD) in a cohort of Italian patients | ||
| 520 | |a METHODS: One hundred and ninety-six consecutive Italian patients satisfying the ISG criteria for BD were followed up for 8 years, and 180 healthy age- and sex-matched blood donors were molecularly genotyped for the CCR5Δ32 polymorphism. A standard microlymphocytotoxicity technique was used to serotype HLA-B51. The patients were subgrouped on the basis of the presence or absence of clinical manifestations | ||
| 520 | |a RESULTS: The distribution of the CCR5Δ32 genotype differed between BD patients and controls (P = 0.02). The CCR5Δ32 allele was more common in BD patients than in controls [P = 0.02, odds ratio (OR) 2.28 (95% CI 1.1, 4.8)]. Carriers of the CCR5Δ32 allele (Δ32/Δ32 + CCR5/Δ32) were significantly more common in BD patients than in controls [P = 0.02, OR 2.37 (95% CI 1.1, 5.1)]. Population-attributable risk was 7.1%. In categorizing patients according to gender, the association between CCR5Δ32 polymorphism and BD was similar in females and males (ORs 2.76 and 2.0, respectively). No significant differences were found when the frequencies of clinical manifestations were compared between CC5RΔ32 allele carriers and non-carriers | ||
| 520 | |a CONCLUSION: CCR5Δ32 polymorphism is associated with an increased susceptibility to develop BD. Chemokines may have a role in the pathophysiology of BD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a HLA-B Antigens |2 NLM | |
| 650 | 7 | |a HLA-B57 antigen |2 NLM | |
| 650 | 7 | |a Receptors, CCR5 |2 NLM | |
| 700 | 1 | |a Boiardi, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Casali, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Farnetti, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Nicoli, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Sarzi-Puttini, Piercarlo |e verfasserin |4 aut | |
| 700 | 1 | |a Pipitone, Nicolò |e verfasserin |4 aut | |
| 700 | 1 | |a Olivieri, Ignazio |e verfasserin |4 aut | |
| 700 | 1 | |a Cantini, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Salvi, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a La Corte, Renato |e verfasserin |4 aut | |
| 700 | 1 | |a Triolo, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Filippini, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Paolazzi, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology (Oxford, England) |d 1999 |g 51(2012), 12 vom: 19. Dez., Seite 2141-5 |w (DE-627)NLM102581908 |x 1462-0332 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2012 |g number:12 |g day:19 |g month:12 |g pages:2141-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/rheumatology/kes238 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2012 |e 12 |b 19 |c 12 |h 2141-5 | ||